Vinge advised Vimian Group AB on the offering. Vimian Group AB (publ) partly guaranteed rights issue which will provide Vimian with issue proceeds of SEK 1,633...
Vimian Group’s Rights Offering
Oncopeptides AB’s Rights Offering
Vinge advised Oncopeptides AB on the deal. Oncopeptides AB (publ) finalized a fully guaranteed rights issuance which will provide Oncopeptides with issue proceeds of approximately SEK...
Precio Fishbone’s Sale of Shares in a Subsidiary Company
Vinge advised Precio Fishbone AB on the deal. Precio Fishbone AB (publ) completed the sale of approximately 80.1 per cent of the shares in the subsidiary...
Cell Impact’s Rights Offering
Vinge advised Cell Impact AB on the deal. Cell Impact AB (publ) completed a rights issuance which will provide Cell Impact with issue proceeds of SEK 129...
Egetis Therapeutics AB’s Equity Private Placement and Debt Financing
Vinge advised Egetis Therapeutics AB on the deal. Egetis Therapeutics AB (publ), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization...
Xspray Pharma’s SEK 300 Million Rights Issuance
Vinge acted for Xspray Pharma in connection with its rights issue of units. Through the rights issue of units, Xspray (STO:XSPRAY) is expected to receive approximately SEK 300...
Immunovia’s SEK 202 Million Rights Offering
Vinge advised Immunovia on the deal. Immunovia AB (publ) has resolved on a new issue of shares of approximately SEK 202.2 million with preferential right for...
Biotage’s USD 215 Million Acquisition of Astrea Bioseparations
Vinge advised Biotage AB on the deal. Global investment firm KKR’s life science platform Gamma Biosciences has sold Astrea Bioseparations, a company focused on helping to bring small...
Egetis Therapeutics’ SEK 210 Million Directed Share Issue
Vinge has advised Egetis Therapeutics AB on the deal. Egetis Therapeutics AB (publ), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization...
Hansa Biopharma’s SEK 415.9 Million Directed Share Issue
Vinge has advised Hansa Biopharma on the deal. Hansa Biopharma announced directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs....
Oncopeptides’ €30 Million Loan Agreement With European Investment Bank
Vinge has advised Oncopeptides on the deal. Wigge & Partners advised the European Investment Bank (EIB). The loan agreement with the European Investment Bank (EIB) grants...
Re:NewCell’s Shares Offering
Baker McKenzie advised Nordea and Pareto on the deal. Vinge has advised Re:NewCell. Re:NewCell AB (publ) has carried out a primary issuance of shares of approximately...